Abnormal glucose metabolism in patients with malignant tumors

Our trial aimed to investigate the prevalence and characteristics of abnormal glucose metabolism in patients with malignant tumors to provide a basis for further intervention. A total of 1045 patients who had been diagnosed with malignant tumors and hospitalized were surveyed. The total prevalence of diabetes mellitus (DM) and impaired fasting glucose (IFG) was 39.1% (409/1045); that is, 16.4% (171/1045) for DM and 22.8% (238/1045) for IFG. The difference in the prevalence of abnormal glucose metabolism in different groups (i.e., age, sex, tumor type, chemotherapy cycle, and chemotherapy regimen) was statistical significance (P<0.05), especially that in the different chemotherapy cycle and regimen groups. The BMI, triglycerides, and total cholesterol in the DM and impaired glucose regulation groups were slightly higher than those in the normal glucose tolerance group; blood insulin was slightly lower. However, these differences were not statistically different (P>0.05). Age (B=1.52), chemotherapy (B=0.85), and tumor type (B=0.64) were incorporated into the equation for logistic multivariate analysis (P<0.05). High prevalence of abnormal glucose metabolism was observed in patients with malignant tumors, especially after multi-cycle, platinum-containing, or taxane-containing chemotherapy. Early intervention of abnormal glucose metabolism is important in treating malignant tumors. Age, chemotherapy regimen, and tumor type may be independent factors for abnormal glucose metabolism in malignant tumors.